Skip to main content

Opening Day: Cancer 'Killer' Nkarta Soars After Coming Public

Nkarta, which is developing "natural killer-based cell therapies" to treat cancer saw its stock surge on its first day of public trading.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.